Sun Pharma Advanced Research Company Limited (Sparc) (NSE: SPARC) and Strides Pharma Science Limited (Star) (NSE: STAR) are both listed in the Pharmaceuticals industry. Sun Pharma Advanced Research Company has a market capitalisation of ₹6,834 Cr and Strides Pharma Science ₹9,212 Cr, as of 16 Nov 2026. Their P/E ratios are 4.4 and 16.8 respectively. Return on equity is 2.77% for Sun Pharma Advanced Research Company and 20.03% for Strides Pharma Science. Over one year, Sun Pharma Advanced Research Company's share price is up 54.4% and Strides Pharma Science's is up 7.0%.
| Metric | Sun Pharma Advanced Research Company | Strides Pharma Science |
|---|---|---|
| NSE Symbol | SPARC | STAR |
| BSE Code | 532872 | 532531 |
| Share Price | ₹206.50 | ₹1,008.70 |
| Market Cap | ₹6,834 Cr | ₹9,212 Cr |
| P/E Ratio | 4.4 | 16.8 |
| Return on Equity | 2.77% | 20.03% |
| Return on Assets | 79.74% | 6.26% |
| Dividend Yield | — | 0.49% |
| Beta (1Y) | 0.82 | 0.43 |
| 1-Year Price Change | +54.4% | +7.0% |
| 3-Month Price Change | +0.8% | +2.6% |
| 52-Week Range | ₹108.00 – ₹289.00 | ₹768.65 – ₹1,260.90 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹30 Cr | ₹1,430 Cr |
| Quarterly Net Profit | ₹-24 Cr | ₹134 Cr |
| Net Margin | -81.2% | 9.4% |
| EPS (Basic, Quarter) | ₹-0.75 | ₹14.19 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Bengaluru, Karnataka |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clini…
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer …
Strides Pharma Science has a market capitalisation of ₹9,212 Cr, against ₹6,834 Cr for Sun Pharma Advanced Research Company as of 16 Nov 2026, about 1.3 times the size by market cap.
Sun Pharma Advanced Research Company has a P/E of 4.4 and Strides Pharma Science a P/E of 16.8 as of 16 Nov 2026.
Sun Pharma Advanced Research Company has a return on equity of 2.77% and Strides Pharma Science 20.03%.
Sun Pharma Advanced Research Company's share price is up 54.4% over one year and Strides Pharma Science's is up 7.0%.
Sun Pharma Advanced Research Company reported revenue of ₹30 Cr and net profit of ₹-24 Cr for Q2 FY27. Strides Pharma Science reported revenue of ₹1,430 Cr and net profit of ₹134 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.